Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rein Therapeutics (RNTX) Depreciation & Amortization (CF) (2016 - 2025)

Rein Therapeutics (RNTX) has disclosed Depreciation & Amortization (CF) for 10 consecutive years, with $1000.0 as the latest value for Q2 2025.

  • Quarterly Depreciation & Amortization (CF) fell 75.0% to $1000.0 in Q2 2025 from the year-ago period, while the trailing twelve-month figure was $1000.0 through Dec 2025, down 98.41% year-over-year, with the annual reading at $1000.0 for FY2025, 98.41% down from the prior year.
  • Depreciation & Amortization (CF) for Q2 2025 was $1000.0 at Rein Therapeutics, down from $4000.0 in the prior quarter.
  • The five-year high for Depreciation & Amortization (CF) was $59000.0 in Q1 2024, with the low at $1000.0 in Q2 2025.
  • Average Depreciation & Amortization (CF) over 5 years is $31533.3, with a median of $40000.0 recorded in 2021.
  • The sharpest move saw Depreciation & Amortization (CF) tumbled 97.14% in 2021, then surged 1950.0% in 2022.
  • Over 5 years, Depreciation & Amortization (CF) stood at $40000.0 in 2021, then increased by 7.5% to $43000.0 in 2022, then grew by 20.93% to $52000.0 in 2023, then tumbled by 92.31% to $4000.0 in 2024, then tumbled by 75.0% to $1000.0 in 2025.
  • According to Business Quant data, Depreciation & Amortization (CF) over the past three periods came in at $1000.0, $4000.0, and $59000.0 for Q2 2025, Q2 2024, and Q1 2024 respectively.